

Mental Disorders Screening

Dementia: IHDS

Anxiety: GAD-2

Anxiety: GAD-7

Depression: PHQ-2

Depression: PHQ-9

PTSD: PC-PTSD-5

Substance Use Screening

Alcohol: AUDIT-C

Alcohol: CAGE

CAGE-AID

Drug Use: TICS

Opioid: Risk Tool

Clinical Calculators

APRI Calculator

BMI Calculator

CrCl Calculator

CTP Calculator

FIB-4 Calculator

FEPO4 Calculator

GFR Calculator

Generalized Anxiety Disorder 2-item (GAD-2) Share

The Generalized Anxiety Disorder 2-item (GAD-2) is a very brief and easy to perform initial screening tool for generalized anxiety disorder.¹

Over the **last 2 weeks**, how often have you been bothered by the following problems?

1. Feeling nervous, anxious or on edge

<input type="radio"/> 0	<input type="radio"/> +1	<input type="radio"/> +2	<input type="radio"/> +3
-------------------------	--------------------------	--------------------------	--------------------------

2. Not being able to stop or control worrying

<input type="radio"/> 0	<input type="radio"/> +1	<input type="radio"/> +2	<input type="radio"/> +3
-------------------------	--------------------------	--------------------------	--------------------------

GAD-2 score obtained by adding score for each question (total points)

Interpretation:

A score of 3 points is the preferred cut-off for identifying possible cases and in which further diagnostic evaluation for generalized anxiety disorder is warranted. Using a cut-off of 3 the GAD-2 has a sensitivity of 86% and specificity of 83% for diagnosis generalized anxiety disorder.

Performance as Screening Tool for Anxiety Disorders

Although designed as a screening tool for generalized anxiety, the GAD-2 is also performs reasonably well as a screening tool for three other common anxiety disorders—Panic Disorder, Social Anxiety Disorder, and Posttraumatic Stress Disorder.¹

Performance of GAD-2 as Screening Tool for Anxiety Disorders³
(Using GAD-2 Score Cut-off of ≥3)

Test	Sensitivity	Specificity	Positive Likelihood Ratio
Generalized Anxiety Disorder	86%	83%	5.0
Panic Disorder	76%	81%	4.1
Social Anxiety Disorder	70%	81%	3.6
Post-Traumatic Stress Disorder	59%	81%	3.1
Any Anxiety Disorder	65%	88%	5.2

Sources

1. Kroenke K, Spitzer RL, Williams JB, Monahan PO, Löwe B. Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. *Ann Intern Med.* 2007;146:317-25.

Acknowledgement

The GAD-2 was based on the GAD-7, which was developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.

This calculator operates entirely from your device.
No input variables or data is transmitted between your computer and our servers.

Funded by
**Health Resources and Services
Administration (HRSA)**

Created at

An AETC Program

Part of

CME provided by

CNE provided by

Antiretroviral Medications

Single-Tablet Regimens
Entry Inhibitors
Long-Acting Injectable Regimens
Nucleoside Reverse Transcriptase Inhibitors
Non-Nucleoside Reverse Transcriptase Inhibitors
Integrase Inhibitors
Nucleoside Reverse Transcriptase Translocation Inhibitors
Protease Inhibitors
Pharmacokinetic Enhancers

Course Modules

Screening and Diagnosis
Basic HIV Primary Care
Antiretroviral Therapy
Co-Occurring Conditions
Prevention of HIV
Key Populations

Question Bank CNE/CME

Clinical Challenges
Clinical Consultation
Master Bibliography

Contributors**Tools & Calculators**

Clinical Calculators
Mental Disorders Screening
Substance Use Screening

Copyright © 2021 National HIV Curriculum
Version 2.14.3-hiv-8 - AWS

[Contact Us](#) | [Terms and Conditions](#) | [Privacy Policy](#)
[CE \(CNE/CME\) Notices](#) | [Copyright and Attribution Notices](#)

The National HIV Curriculum is an AIDS Education and Training Center (AETC) Program supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling \$1,000,000 with 0% financed with non-governmental sources. The content in this presentation are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government.

part of the IDEA platform